
Beating Expectations: A Peek into Fate Therapeutics’ Q4 Earnings and the Progress of Their Autoimmunity and Oncology Programs
FATE Therapeutics: A Look into Q4 Losses, Revenues, and Innovative Pipelines FATE Therapeutics, a leading biotech company specializing in the development of programmed cellular immunotherapies for cancer and immune disorders, recently reported its fourth-quarter and full-year 2021 financial results. The company’s financials showed a narrower loss and increased revenues compared to the same period the…